Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

Table 3 Hematologic and serologic parameters Day -14 to end of treatment (EOT)

Patient #	White blood cells (× 10⁹/l) RR 3.9-10.7				Absolute lymphocytes (× 10⁹/l) RR 0.9-4.3				Absolute neutrophils (× 10⁹/l) RR 2.0-7.2
	Day -14	Day 1	Day 14 (± 1)	EOT	Day -14	Day 1	Day 14 (± 1)	EOT	Day -14	Day 1	Day 14 (± 1)	EOT
2	11.2	6.0	8.3	3.8	1.7	1.6	1.7	2.0	8.9	4.1	6.4	1.6^L1
8	6.3	15.1	12.4	8.1	0.8^L2	0.9	1.3	1.0	5.0	13.7	10.6	7.0
3	5.7	11.1	8.1	4.7	0.9	0.7^L2	0.5^L2	0.2^L3	4.4	10.1	7.4	4.3
5	2.8^L2	15.6	N/A	N/A	1.0	3.4	N/A	N/A	1.6^L1	10.6	N/A	N/A
13	14.7	5.6	8.5	7.6	1.5	0.7^L2	0.5^L3	0.7^L2	13.1	4.7	7.8	6.5
14	15.5 ^a	15.2	8.3^b	7.1	0.9^a	1.8	0.8^{L1, b}	0.8^L1	13.7 ^a	12.9	7.0^b	5.7
	CD4 ⁺ (cells/μl) [%] RR 404-1612 [33-58]				Complement C3 (g/l) RR 0.9-1.8				Anti-dsDNA (IU/ml) < 30.0, negative; 30-75, borderline; > 75, positive
Patient #	Day 1	Day 28 (± 2)	EOT		Day 1	Day 14 (± 1)	EOT		Day -14	Day 1	Day 14 (± 1)	EOT
2	489 [25.8^L]	1731 [34.1]	980 [44.6]		0.686^L	0.904	0.721^L		917.2	375.7	168.1	463.9
8	277^L2 [23.5^L]^c	273^L2 [29.7^L]	195^L3 [24.0^L]		0.915	1.150	1.070		325.5	306.1	97.6	20.1
3	N/A	56^L3 [13.7^L]	45^L4 [21.4^L]		0.533^L	0.800^L	0.906		155.3	77.6	37.5	< 12.3
5	529 [22.1^L]	809 [30.1^L]	603 [46.8]		1.030	1.630	1.700		56.7	43.0	34.3	12.6
13	240^L2 [38.7]	95^L3 [23.8^L]	163^L3 [19.3^L]		0.462^L	0.717	0.909		87.5	26.0	13.0	12.7
14	135^L3 [19.1^L]	N/A	158^L3 [19.9^L]		0.434^L	0.541^b	0.609^L		349.6	88.1	28.8^b	20.1

Patients #2 and #8 randomized to placebo; Patients #3, #5, #13 and #14 randomized to atacicept 150 mg subcutaneously twice weekly (4 weeks), then 150 mg weekly (48 weeks). N/A, not available; RR, reference range. Values > ULN indicated in italics; ^LValues < LLN, with Grade (1 to 4), where applicable. ^aMeasured Day -10; ^bMeasured Day 18; ^cMeasured Day 4.

ISSN: 1478-6362